國務院:完善中醫藥價格和醫保政策 鼓勵中藥材產業化助企業走出去
國務院辦公廳印發《「十四五」中醫藥發展規劃》提出,到2025年,中醫藥健康服務能力明顯增強,中醫藥高質量發展政策和體系進一步完善,中醫藥振興發展取得積極成效,在健康中國建設中的獨特優勢得到充分發揮。規劃提出加快中醫藥開放發展等十大任務。
規劃提出,大力發展中醫藥服務貿易,高質量建設國家中醫藥服務出口基地;推動中醫藥海外本土化發展,鼓勵發展「互聯網+中醫藥貿易」。逐步完善中醫藥「走出去」相關措施,開展中醫藥海外市場政策研究,助力中醫藥企業「走出去」及推動中藥類產品海外註冊和應用。
規劃並提出,在醫療服務價格動態調整中重點考慮中醫醫療服務項目。醫療機構炮製使用的中藥飲片、中藥制劑實行自主定價,符合條件的按程序納入基本醫療保險支付範圍;符合條件的中醫醫療服務項目和中藥按程序納入基本醫療保險支付範圍;以及探索符合中醫藥特點的醫保支付方式,鼓勵實行中西醫同病同效同價。
規劃還提出,在傳染病防治法、突發公共衛生事件應對法等法律法規制修訂中,研究納入堅持中西醫並重以及中西醫結合、中西藥並用、加強中醫救治能力建設等相關內容,推動建立有效機制等。(ta/w) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.